US 12,215,169 B2
Anti-complement C1s antibodies and uses thereof
Peter Van Vlasselaer, Portola Valley, CA (US); Graham Parry, Burlington, MA (US); Nancy E. Stagliano, South San Francisco, CA (US); and Sandip Panicker, South San Francisco, CA (US)
Assigned to Bioverativ USA Inc., Waltham, MA (US)
Filed by Bioverativ USA Inc., Waltham, MA (US)
Filed on Dec. 20, 2021, as Appl. No. 17/556,061.
Application 17/556,061 is a division of application No. 16/575,265, filed on Sep. 18, 2019, abandoned.
Application 16/575,265 is a division of application No. 15/385,610, filed on Dec. 20, 2016, granted, now 10,457,745.
Application 15/385,610 is a continuation of application No. 14/691,869, filed on Apr. 21, 2015, granted, now 9,562,106.
Application 14/691,869 is a continuation of application No. PCT/US2013/066783, filed on Oct. 25, 2013.
Claims priority of provisional application 61/779,217, filed on Mar. 13, 2013.
Claims priority of provisional application 61/754,205, filed on Jan. 18, 2013.
Claims priority of provisional application 61/718,519, filed on Oct. 25, 2012.
Prior Publication US 2022/0185912 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/40 (2013.01) [C12Y 304/21042 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 21 Claims
 
1. One or more nucleic acids encoding an antibody that binds to complement C1s protein, wherein the antibody comprises:
a light chain complementarity-determining region-1 (CDR-L1) sequence, a light chain complementarity-determining region-2 (CDR-L2) sequence, and a light chain complementarity-determining region-3 (CDR-L3) sequence of an antibody light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 15; and
a heavy chain complementarity-determining region-1 (CDR-H1) sequence, a heavy chain complementarity-determining region-2 (CDR-H2) sequence, and a heavy chain complementarity-determining region-3 (CDR-H3) sequence of an antibody heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 16.